Literature DB >> 21276222

Low-intensity blue-enriched white light (750 lux) and standard bright light (10,000 lux) are equally effective in treating SAD. A randomized controlled study.

Ybe Meesters1, Vera Dekker, Luc J M Schlangen, Elske H Bos, Martine J Ruiter.   

Abstract

BACKGROUND: Photoreceptor cells containing melanopsin play a role in the phase-shifting effects of short-wavelength light. In a previous study, we compared the standard light treatment (SLT) of SAD with treatment using short-wavelength blue-enriched white light (BLT). Both treatments used the same illuminance (10,000 lux) and were equally highly effective. It is still possible, however, that neither the newly-discovered photoreceptor cells, nor the biological clock play a major role in the therapeutic effects of light on SAD. Alternatively, these effects may at least be partly mediated by these receptor cells, which may have become saturated as a result of the high illuminances used in the therapy. This randomized controlled study compares the effects of low-intensity BLT to those of high-intensity SLT.
METHOD: In a 22-day design, 22 patients suffering from a major depression with a seasonal pattern (SAD) were given light treatment (10,000 lux) for two weeks on workdays. Subjects were randomly assigned to either of the two conditions, with gender and age evenly distributed over the groups. Light treatment either consisted of 30 minutes SLT (5000 °K) with the EnergyLight® (Philips, Consumer Lifestyle) with a vertical illuminance of 10,000 lux at eye position or BLT (17,000 °K) with a vertical illuminance of 750 lux using a prototype of the EnergyLight® which emitted a higher proportion of short-wavelengths. All participants completed questionnaires concerning mood, activation and sleep quality on a daily basis. Mood and energy levels were also assessed on a weekly basis by means of the SIGH-SAD and other assessment tools.
RESULTS: On day 22, SIGH-SAD ratings were significantly lower than on day 1 (SLT 65.2% and BLT 76.4%). On the basis of all assessments no statistically significant differences were found between the two conditions.
CONCLUSION: With sample size being small, conclusions can only be preliminary. Both treatment conditions were found to be highly effective. The therapeutic effects of low-intensity blue-enriched light were comparable to those of the standard light treatment. Saturation effects may play a role, even with a light intensity of 750 lux. The therapeutic effects of blue-enriched white light in the treatment of SAD at illuminances as low as 750 lux help bring light treatment for SAD within reach of standard workplace and educational lighting systems.

Entities:  

Mesh:

Year:  2011        PMID: 21276222      PMCID: PMC3042929          DOI: 10.1186/1471-244X-11-17

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


  32 in total

1.  A novel human opsin in the inner retina.

Authors:  I Provencio; I R Rodriguez; G Jiang; W P Hayes; E F Moreira; M D Rollag
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

2.  Lux vs. wavelength in light treatment of Seasonal Affective Disorder.

Authors:  J L Anderson; C A Glod; J Dai; Y Cao; S W Lockley
Journal:  Acta Psychiatr Scand       Date:  2009-02-03       Impact factor: 6.392

3.  Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN.

Authors:  Dennis M Dacey; Hsi-Wen Liao; Beth B Peterson; Farrel R Robinson; Vivianne C Smith; Joel Pokorny; King-Wai Yau; Paul D Gamlin
Journal:  Nature       Date:  2005-02-17       Impact factor: 49.962

4.  Morning and evening light treatment of seasonal affective disorder: response, relapse and prediction.

Authors:  Y Meesters; J H Jansen; P A Lambers; A L Bouhuys; D G Beersma; R H van den Hoofdakker
Journal:  J Affect Disord       Date:  1993-07       Impact factor: 4.839

5.  Light therapy for seasonal affective disorder with blue narrow-band light-emitting diodes (LEDs).

Authors:  Gena Glickman; Brenda Byrne; Carissa Pineda; Walter W Hauck; George C Brainard
Journal:  Biol Psychiatry       Date:  2005-09-13       Impact factor: 13.382

6.  Extraocular light therapy in winter depression: a double-blind placebo-controlled study.

Authors:  K M Koorengevel; M C Gordijn; D G Beersma; Y Meesters; J A den Boer; R H van den Hoofdakker; S Daan
Journal:  Biol Psychiatry       Date:  2001-11-01       Impact factor: 13.382

7.  Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity.

Authors:  S Hattar; H W Liao; M Takao; D M Berson; K W Yau
Journal:  Science       Date:  2002-02-08       Impact factor: 47.728

Review 8.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

9.  Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy.

Authors:  N E Rosenthal; D A Sack; J C Gillin; A J Lewy; F K Goodwin; Y Davenport; P S Mueller; D A Newsome; T A Wehr
Journal:  Arch Gen Psychiatry       Date:  1984-01

10.  Narrow-band blue-light treatment of seasonal affective disorder in adults and the influence of additional nonseasonal symptoms.

Authors:  Robert E Strong; Barrie K Marchant; Frederick W Reimherr; Erika Williams; Poonam Soni; Ruth Mestas
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

View more
  24 in total

1.  [The current state of research in bright light therapy].

Authors:  Daniela Bassa; Markus Canazei; Hartmann Hinterhuber; Elisabeth M Weiss
Journal:  Neuropsychiatr       Date:  2013-06-21

2.  The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose.

Authors:  E M McGlashan; L S Nandam; P Vidafar; D R Mansfield; S M W Rajaratnam; S W Cain
Journal:  Psychopharmacology (Berl)       Date:  2018-09-15       Impact factor: 4.530

3.  The post illumination pupil response is reduced in seasonal affective disorder.

Authors:  Kathryn Roecklein; Patricia Wong; Natalie Ernecoff; Megan Miller; Shannon Donofry; Marissa Kamarck; W Michael Wood-Vasey; Peter Franzen
Journal:  Psychiatry Res       Date:  2013-07-01       Impact factor: 3.222

4.  Are short (blue) wavelengths necessary for light treatment of seasonal affective disorder?

Authors:  J L Anderson; M A St Hilaire; R R Auger; C A Glod; S J Crow; A N Rivera; S M Fuentes Salgado; S J Pullen; T K Kaufman; A J Selby; D J Wolfe
Journal:  Chronobiol Int       Date:  2016-08-05       Impact factor: 2.877

Review 5.  Chronobiological Therapy for Mood Disorders.

Authors:  Sara Dallaspezia; Masahiro Suzuki; Francesco Benedetti
Journal:  Curr Psychiatry Rep       Date:  2015-12       Impact factor: 5.285

6.  Human phase response curve to a single 6.5 h pulse of short-wavelength light.

Authors:  Melanie Rüger; Melissa A St Hilaire; George C Brainard; Sat-Bir S Khalsa; Richard E Kronauer; Charles A Czeisler; Steven W Lockley
Journal:  J Physiol       Date:  2012-10-22       Impact factor: 5.182

Review 7.  Melanopsin, photosensitive ganglion cells, and seasonal affective disorder.

Authors:  Kathryn A Roecklein; Patricia M Wong; Megan A Miller; Shannon D Donofry; Marissa L Kamarck; George C Brainard
Journal:  Neurosci Biobehav Rev       Date:  2012-12-31       Impact factor: 8.989

8.  Effects of blue light and caffeine on mood.

Authors:  Johan G Ekström; C Martyn Beaven
Journal:  Psychopharmacology (Berl)       Date:  2014-03-04       Impact factor: 4.530

Review 9.  Circadian entrainment and its role in depression: a mechanistic review.

Authors:  G S Lall; L A Atkinson; S A Corlett; P J Broadbridge; D R Bonsall
Journal:  J Neural Transm (Vienna)       Date:  2012-07-14       Impact factor: 3.575

10.  Reading increases ocular illuminance during light treatment.

Authors:  Aamar Sleemi; Mary A Johnson; Kelly J Rohan; Olaoluwa Okusaga; Timileyin Adediran; Hyacinth Uzoma; Chantelle Walsh; Gloria Reeves; Teodor T Postolache
Journal:  Int J Adolesc Med Health       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.